A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 110
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : DP IV
Long Form : dipeptidyl peptidase IV
No. Year Title Co-occurring Abbreviation
2013 Inhibition of dipeptidyl peptidase activity by flavonol glycosides of guava (Psidium guajava L.): a key to the beneficial effects of guava in type II diabetes mellitus. ---
2012 Activities of proline-specific peptidases in brain structures of rats with experimental anxiety-depressive state caused by administration of dipeptidyl peptidase IV inhibitor in the early postnatal period. PEP
2011 Divergent actions by inhibitors of DP IV and APN family enzymes on CD4+ Teff cell motility and functions. APN, Teff, Th
2011 PETIR-001, a dual inhibitor of dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN), ameliorates experimental autoimmune encephalomyelitis in SJL/J mice. APN, CNS, EAE
2010 The dipeptidyl peptidase IV family in cancer and cell biology. ---
2009 Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice. DP II, DP8, DP9
2009 Simultaneous absolute quantification of the glucose-dependent insulinotropic polypeptides GIP1-42 and GIP3-42 in mouse plasma by LC/ESI-MS/MS: preclinical evaluation of DP-IV inhibitors. LLOQ
2009 The in vivo expression of dipeptidyl peptidases 8 and 9. ---
2008 Modulation of cytokine production and silica-induced lung fibrosis by inhibitors of aminopeptidase N and of dipeptidyl peptidase-IV-related proteases. APN
10  2008 Non-substrate peptides influencing dipeptidyl peptidase IV/CD26 activity and immune cell function. ---
11  2007 3D-QSAR studies on fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors by CoMFA and CoMSIA. ---
12  2007 Fibroblast activation protein and chronic liver disease. FAP
13  2007 Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts. ---
14  2007 The ectopeptidases dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN) and their related enzymes as possible targets in the treatment of skin diseases. APN, cAAP, FAP
15  2006 Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus. ---
16  2006 Dipeptidylpeptidase IV (DPIV) and alanyl-aminopeptidases (AAPs) as a new target complex for treatment of autoimmune and inflammatory diseases-proof of concept in a mouse model of colitis. AAPs
17  2006 Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY. PYY
18  2006 Inhibitors of dipeptidyl peptidase IV and aminopeptidase N target major pathogenetic steps in acne initiation. APN
19  2005 Development and resolution of experimental colitis in mice with targeted deletion of dipeptidyl peptidase IV. DSS, GLP-2, PCNA
20  2005 Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? ---
21  2005 Elevation of dipeptidylpeptidase iv activities in the prostate peripheral zone and prostatic secretions of men with prostate cancer: possible prostate cancer disease marker. EPS
22  2005 Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. ECM, FAP, HSC
23  2005 Molecular characterization of a novel dipeptidyl peptidase like 2-short form (DPL2-s) that is highly expressed in the brain and lacks dipeptidyl peptidase activity. DPL2-s, DPL2-s
24  2005 Pyrazolidine derivatives with heteroaryl urea as dipeptidyl peptidase IV inhibitors. ---
25  2005 Rigidity and flexibility of dipeptidyl peptidase IV: crystal structures of and docking experiments with DPIV. ---
26  2005 Synthesis and evaluation of pyrazolidine derivatives as dipeptidyl peptidase IV (DP-IV) inhibitors. ---
27  2004 A rapid in vitro screening for delivery of peptide-derived peptidase inhibitors as potential drug candidates via epithelial peptide transporters. ---
28  2004 Simultaneous determination of incretin hormones and their truncated forms from human plasma by immunoprecipitation and liquid chromatography-mass spectrometry. ---
29  2004 Synthesis and DP-IV inhibition of cyano-pyrazoline derivatives as potent anti-diabetic agents. ---
30  2004 The purification and characterisation of novel dipeptidyl peptidase IV-like activity from bovine serum. IEF
31  2003 Biological significance of aminopeptidase N/CD13 in thyroid carcinomas. APN, FTCs, NDRG
32  2003 Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. GIP, GLP-1, STZ
33  2003 Dipeptidyl peptidase IV on activated T cells as a target molecule for therapy of rheumatoid arthritis. ---
34  2003 Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. GLP-1, HFD
35  2003 The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). GIP, PACAP38
36  2002 Biological actions and therapeutic potential of the glucagon-like peptides. ---
37  2002 Conformation of N-terminal HIV-1 Tat (fragment 1-9) peptide by NMR and MD simulations. PPII
38  2002 Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. GIP, VDF
39  2002 Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. GIP, GLP-1, VDF
40  2002 Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. GIP, GLP-1, OGTTs
41  2002 Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. GLP-1
42  2002 The role of dipeptidyl peptidase IV (DP IV) enzymatic activity in T cell activation and autoimmunity. ---
43  2002 Transcellular proteolysis demonstrated by novel cell surface-associated substrates of dipeptidyl peptidase IV (CD26). ---
44  2001 Expression and activity of ectopeptidases in fibrillating human atria. AF, APN, BK, CPM
45  2001 Inhibition of dipeptidyl peptidase IV (DP IV, CD26) activity abrogates stress-induced, cytokine-mediated murine abortions. IFN, IL
46  2001 Minireview: the glucagon-like peptides. ---
47  2001 Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo. EAE
48  2000 A new type of fluorogenic substrates for determination of cellular dipeptidyl peptidase IV (DP IV/CD26) activity. ---
49  2000 Amino-terminal truncation of procalcitonin, a marker for systemic bacterial infections, by dipeptidyl peptidase IV (DP IV). PCT
50  2000 Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. CD, GLP-2, IBD, UC
51  2000 Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPIV-resistant analogs. pGlu
52  2000 Down-regulation of T cell activation following inhibition of dipeptidyl peptidase IV/CD26 by the N-terminal part of the thromboxane A2 receptor. TXA2R
53  2000 Effects of nonapeptides derived from the N-terminal structure of human immunodeficiency virus-1 (HIV-1) Tat on suppression of CD26-dependent T cell growth. HIV-1, PBMC
54  2000 Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. GLP
55  2000 Metabolism of glucagon by dipeptidyl peptidase IV (CD26). ---
56  2000 Potent inhibitors of dipeptidyl peptidase IV and their mechanisms of inhibition. ---
57  2000 Thioxo amino acid pyrrolidides and thiazolidides: new inhibitors of proline specific peptidases. APP, CS-N, DP II, POP, Pyrr, Thia
58  1999 Diprotin A, an inhibitor of dipeptidyl aminopeptidase IV(EC 3.4.14.5) produces naloxone-reversible analgesia in rats. ---
59  1998 1H NMR conformational study on N-terminal nonapeptide sequences of HIV-1 Tat protein: a contribution to structure-activity relationships. ---
60  1998 Anti-arthritic effects of the novel dipeptidyl peptidase IV inhibitors TMC-2A and TSL-225. ---
61  1998 Endopeptidase 24.11/CD10 is down-regulated in renal cell cancer. APA, APN, RCC
62  1998 Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. GIP, GLP, Ile-thiazolidide
63  1997 The N-terminal structure of HIV-1 Tat is required for suppression of CD26-dependent T cell growth. AIDS, HIV-1
64  1997 TMC-2A, -2B and -2C, novel dipeptidyl peptidase IV inhibitors produced by Aspergillus oryzae A374. I. Taxonomy of producing strain, fermentation, and biochemical properties. ---
65  1996 A new mechanism in serine proteases catalysis exhibited by dipeptidyl peptidase IV (DP IV)--Results of PM3 semiempirical thermodynamic studies supported by experimental results. ---
66  1996 The enteroinsular axis in dipeptidyl peptidase IV-negative rats. GIP
67  1996 The N-terminal X-X-Pro sequence of the HIV-1 Tat protein is important for the inhibition of dipeptidyl peptidase IV (DP IV/CD26) and the suppression of mitogen-induced proliferation of human T cells. ---
68  1995 Functional role of CD26 on human B lymphocytes. NK
69  1995 Inhibition of dipeptidyl peptidase IV (DP IV) by anti-DP IV antibodies and non-substrate X-X-Pro- oligopeptides ascertained by capillary electrophoresis. Gly-Pro-pNA
70  1995 Stimulation of the expression and the enzyme activity of aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 on human renal cell carcinoma cells and renal tubular epithelial cells by T cell-derived cytokines, such as IL-4 and IL-13. APN, GM-CSF, IFN-gamma, PCR, TGF-beta1, TNF-alpha
71  1994 Developmental changes of enzymes involved in peptide degradation in isolated rat brain microvessels. ALP, APA, APM, BBB, gamma-GT
72  1994 Dipeptidyl peptidase IV (DP IV) activity in serum and on lymphocytes of MRL/Mp-lpr/lpr mice correlates with disease onset. ---
73  1994 Dipeptidyl peptidase IV and aminopeptidase in burn wound exudates: implications for wound healing. AP
74  1994 Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat's immunosuppressive activity. HIV-1, mAb
75  1994 Solution structures of active and inactive forms of the DP IV (CD26) inhibitor Pro-boroPro determined by NMR spectroscopy. ---
76  1993 Mechanism of HIV-1 Tat induced inhibition of antigen-specific T cell responsiveness. ---
77  1993 Peptidyl ammonium methyl ketones as substrate analog inhibitors of proline-specific peptidases. PEP
78  1993 Separation of L-Pro-DL-boroPro into its component diastereomers and kinetic analysis of their inhibition of dipeptidyl peptidase IV. A new method for the analysis of slow, tight-binding inhibition. ---
79  1992 Involvement of dipeptidyl peptidase IV in an in vivo immune response. BSA
80  1992 The probable conformation of substrates recognized by dipeptidyl-peptidase IV and some aspects of the catalytic mechanism derived from theoretical investigations. ---
81  1992 [Differentiation of fetal lymphocytes with the DP-(dipeptidylpeptidase-) IV technique]. ---
82  1991 Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes. ---
83  1991 Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. DP-IV
84  1991 N-terminal amino-acid sequence of pig kidney dipeptidyl peptidase IV solubilized by autolysis. ---
85  1990 Dipeptidyl peptidase IV (DP IV) and superoxide dismutase activity in thymus-derived lymphocytes: effects of inhibitory peptides and Zn2+ in vitro. SOD
86  1990 Dipeptidyl peptidase IV in the immune system. Cytofluorometric evidence for induction of the enzyme on activated T lymphocytes. ---
87  1990 [Characterization of T lymphocyte defects in patients with Hodgkin's disease using enzyme chemical markers]. ANAE, SE
88  1990 [Dipeptidylpeptidase IV activity in human lymphocytes in hepatobiliary diseases]. MNC
89  1989 A kinetic fluorometric assay of dipeptidyl peptidase IV in viable human blood mononuclear cells. ---
90  1989 Dipeptidyl peptidase IV in human T lymphocytes. Impaired induction of interleukin 2 and gamma interferon due to specific inhibition of dipeptidyl peptidase IV. IL-2
91  1988 Dipeptidyl peptidase IV--subcellular localization, activity and kinetics in lymphocytes from control subjects, immunodeficient patients and cord blood. CLL, CVH
92  1988 Dipeptidylpeptidase IV--inactivation with N-peptidyl-O-aroyl hydroxylamines. ---
93  1988 Metabolism of D-proline beta-casomorphin derivatives in the rat brain. D-Pro4-beta CM, DT-D-Pro4-beta CM, i.c.v
94  1988 Molecular interactions in intermediate and transition states in the self-stimulated inhibition of enzymes. DFP
95  1988 [Detection of dipeptidyl peptidase IV in follicular fluid--initial report]. ---
96  1987 Dipeptidyl peptidase IV (DP IV), a functional marker of the T lymphocyte system. ---
97  1987 The role of dipeptidyl peptidase IV in human T lymphocyte activation. Inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and immunoglobulin synthesis in vitro. ---
98  1986 Complementary action of dipeptidyl peptidase IV and aminopeptidase M in the digestion of beta-casein. ---
99  1986 Dipeptidyl peptidase IV in human T lymphocytes. An approach to the role of a membrane peptidase in the immune system. ---
100  1986 [Diagnostic value of the enzyme dipeptidyl peptidase IV (DP IV) in abdominal cancers]. ---